Seeking Alpha

Soligenix rises on BARDA contract news

  • Soligenix (SNGX.OB +11.2%) jumps after announcing it has received a contract from the Biomedical Advanced Research and Development Authority for the "preclinical and manufacturing development" of the GI ARS treatment OrbeShield.
  • The initial deal is for two years and can be extended for up to five total years.
  • The contract is valued at up to $26.3M and will help the company "successfully navigate and complete the FDA approval process." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs